

Preliminary HIV Surveillance Annual Report, 2025

San Francisco Department of Public Health, Population Health Division,
Applied Research, Community Health Epidemiology, and Surveillance Branch
(ARCHES)
HIV Epidemiology and Surveillance

Cases Diagnosed as of December 31, 2025 and Reported as of February 3, 2026

Director of Health: Daniel Tsai

Director of Population Health Division: Susan Philip, MD, MPH

Deputy Director of Surveillance, Data and Analytics: Kyle Bernstein, PhD, ScM

Director of HIV Epidemiology and Surveillance: Arpi Terzian, PhD, MPH

25 Van Ness Avenue, Suite 500, San Francisco, CA 94102

Phone (628) 217-6336; Fax (415) 431-0353

Suggested citation:

San Francisco Department of Public Health, Population Health Division, Applied Research, Community Health Epidemiology, and Surveillance Branch (ARCHES), HIV Epidemiology and Surveillance. Preliminary HIV Surveillance Annual Report – 2025. Published April 2025.

Available on the web:

[San Francisco HIV Epidemiology Unit Reports](#)

Note: *The preliminary HIV surveillance annual report is issued on an annual basis prior to the final HIV surveillance annual report published.*

Preliminary HIV Surveillance Annual Report
Cases Diagnosed as of December 31, 2025 and Reported as of February 3, 2026

Contents

Abbreviations.....	ii
HIV Surveillance Summary.....	1
Figure 1. Diagnoses of HIV infection, HIV deaths and persons living with HIV by year, San Francisco, 2002–2025.....	2
Figure 2. Diagnoses of HIV infection stage 3 (AIDS), AIDS deaths and persons living with AIDS by year, San Francisco, 1980–2025.....	2
Figure 3. Continuum of HIV care among persons newly diagnosed with HIV, San Francisco.....	3
Table 1. Diagnoses of HIV infection by age and year of initial HIV diagnosis, San Francisco, 2021–2025.....	4
Table 2. Diagnoses of HIV infection stage 3 (AIDS) by age and year of AIDS diagnosis, San Francisco, 2021–2025.....	5
Table 3. Diagnoses of HIV infection by gender and year of initial HIV diagnosis, San Francisco, 2021–2025.....	6
Table 4. Diagnoses of HIV infection stage 3 (AIDS) by gender and year of AIDS diagnosis, San Francisco, 2021–2025.....	7
Table 5. Diagnoses of HIV infection by race/ethnicity and year of initial HIV diagnosis, San Francisco, 2021–2025.....	8
Table 6. Diagnoses of HIV infection stage 3 (AIDS) by race/ethnicity and year of AIDS diagnosis, San Francisco, 2021–2025.....	9
Table 7. Diagnoses of HIV infection by transmission category and year of initial HIV diagnosis, San Francisco, 2021–2025.....	10
Table 8. Diagnoses of HIV infection stage 3 (AIDS) by transmission category and year of AIDS diagnosis, San Francisco, 2021–2025.....	11
Table 9. Diagnoses of HIV infection, HIV deaths and persons living with HIV by year, San Francisco, 2002–2025.....	12
Table 10. Diagnoses of HIV infection stage 3 (AIDS), AIDS deaths and persons living with AIDS by year, San Francisco, 1980–2025.....	13
Table 10 cont'd. Diagnoses of HIV infection stage 3 (AIDS), AIDS deaths and persons living with AIDS by year, San Francisco, 1980–2025.....	14
Table 11. Persons living with HIV infection by age, gender and race/ethnicity, San Francisco (as of December 31, 2025).....	15
Table 12. Persons living with HIV infection by transmission category, gender and race/ethnicity, San Francisco (as of December 31, 2025).....	16

Preliminary HIV Surveillance Annual Report
Cases Diagnosed as of December 31, 2025 and Reported as of February 3, 2026

Abbreviations

MSM	Men who have sex with men
MSM-PWID	Men who have sex with men and who also inject drugs
PWID	People who inject drugs
TWSM	Trans women who have sex with men
TWSM-PWID	Trans women who have sex with men and who also inject drugs

Preliminary HIV Surveillance Annual Report
Cases Diagnosed as of December 31, 2025 and Reported as of February 3, 2026

HIV Surveillance Summary

San Francisco¹ (as of December 31, 2025)	Number
People living with HIV infection (all disease stages)	15,253
People living with HIV infection ever classified as stage 3 (AIDS)	8,226
Diagnoses of HIV infection	139
Deaths of persons diagnosed with HIV infection	245
Deaths of persons diagnosed with HIV infection ever classified as stage 3 (AIDS)	180
California² (as of December 31, 2023)	
People living with HIV infection (all disease stages)	143,254
People living with HIV infection ever classified as stage 3 (AIDS) ³	63,675
Diagnoses of HIV infection	4,948
Deaths of persons diagnosed with HIV infection	2,252
Deaths of persons diagnosed with HIV infection ever classified as stage 3 (AIDS) ⁴	1,636
United States⁵ (as of December 31, 2023)	
People living with HIV infection (all disease stages)	1,133,768
Diagnoses of HIV infection	39,258
Deaths of persons diagnosed with HIV infection	19,106
Deaths of persons diagnosed with HIV infection ever classified as stage 3 (AIDS) ⁴	14,201

¹ Residents of San Francisco at the time of HIV or AIDS diagnoses.

² California Department of Public Health, Office of AIDS, California HIV Surveillance Report, 2023 (tables 1a, 2a, 3a). https://www.cdph.ca.gov/Programs/CID/DOA/Pages/OA_case_surveillance_reports.aspx. Released April 21, 2025. Accessed January 22, 2026.


³ California Department of Public Health, Office of AIDS, Supplemental Tables to the California HIV Surveillance Report, 2023 (table S3b). https://www.cdph.ca.gov/Programs/CID/DOA/Pages/OA_case_surveillance_reports.aspx. Released May 2025. Accessed January 22, 2026.

⁴ Center for Disease Control and Prevention. HIV diagnoses, deaths, and prevalence of HIV in the United States and 6 Territories and Freely Associated States, 2023 (HIV Monitoring Report Tables 6f). <https://www.cdc.gov/hiv-data/nhss/hiv-diagnoses-deaths-prevalence.html>. Published April 19, 2025. Accessed February 09, 2026.

⁵ Center for Disease Control and Prevention. HIV diagnoses, deaths, and prevalence of HIV in the United States and 6 Territories and Freely Associated States, 2023 (HIV Surveillance Report Tables 1b, 11b, 12b). <https://www.cdc.gov/hiv-data/nhss/hiv-diagnoses-deaths-prevalence.html>. Published April 19, 2025. Accessed February 09, 2026.


Preliminary HIV Surveillance Annual Report
 Cases Diagnosed as of December 31, 2025 and Reported as of February 3, 2026

Figure 1. Diagnoses of HIV infection, HIV deaths and persons living with HIV by year, San Francisco, 2002–2025



Notes: A tabular list of case counts by year from 2002-2025 is presented in Table 9.


Figure 2. Diagnoses of HIV infection stage 3 (AIDS), AIDS deaths and persons living with AIDS by year, San Francisco, 1980–2025



Notes: A tabular list of case counts by year from 1980-2025 is presented in Table 10.

Preliminary HIV Surveillance Annual Report
Cases Diagnosed as of December 31, 2025 and Reported as of February 3, 2026

Figure 3. Continuum of HIV care among persons newly diagnosed with HIV, San Francisco



Notes:

The values inside the bars represent new cases. Percentages are calculated using the number of new diagnoses for the corresponding time period as the denominator and are not nested.

Month/Year of HIV Diagnosis

The month and year of HIV diagnosis are determined based on the earliest date of a positive HIV antibody/antigen test, detectable viral load, or physician-documented diagnosis in absence of sufficient laboratory evidence, and do not consider patient self-report of a positive HIV test. For other parts of this report that assess trends in HIV diagnoses, the year of initial HIV diagnosis takes into account self-report of HIV infection. Therefore, the numbers shown in Figure 3 may differ from other data presented in this report. The numbers displayed inside the bars represent new cases.

Linkage to Care

Linkage to care is measured by the documentation of CD4, viral load or genotype tests performed within one month of diagnosis.

Viral Suppression

Viral suppression is defined as having a viral load below 200 copies/mL within six months of diagnosis. This indicator measures the percentage of individuals diagnosed with HIV who achieve viral suppression at their most recent test during the measurement year. To be included in the denominator, a person must have had at least one viral load test. This measure is not limited to those linked to care within one month of diagnosis.

Preliminary HIV Surveillance Annual Report
Cases Diagnosed as of December 31, 2025 and Reported as of February 3, 2026

Table 1. Diagnoses of HIV infection by age and year of initial HIV diagnosis, San Francisco, 2021–2025

Age at initial HIV diagnosis (years)	Year of initial HIV diagnosis									
	2021		2022		2023		2024		2025	
	No.	%	No.	%	No.	%	No.	%	No.	%
0 - 24	18	10.1	22	13.0	22	15.7	18	12.2	11	7.9
25 - 29	35	19.6	37	21.9	19	13.6	24	16.2	23	16.5
30 - 39	61	34.1	48	28.4	49	35.0	60	40.5	52	37.4
40 - 49	35	19.6	37	21.9	27	19.3	25	16.9	27	19.4
50 - 59	23	12.8	16	9.5	14	10.0	14	9.5	15	10.8
60+	7	3.9	9	5.3	9	6.4	7	4.7	11	7.9
Total	179	100.0	169	100.0	140	100.0	148	100.0	139	100.0

Notes:

Initial HIV diagnosis includes persons diagnosed with HIV infection regardless of disease stage. The initial year of HIV diagnosis was determined based on the earliest date of positive HIV antibody test, positive HIV antigen/antibody combination test, detectable viral load, physician-documented diagnosis in the absence of sufficient laboratory evidence, or self-report of a positive HIV test.

Due to small numbers in the 0–12 and 13–17 age groups, these are not shown separately.

2025 data are incomplete due to delays in data collection, lab reporting, verification, and processing.

Preliminary HIV Surveillance Annual Report
Cases Diagnosed as of December 31, 2025 and Reported as of February 3, 2026

Table 2. Diagnoses of HIV infection stage 3 (AIDS) by age and year of AIDS diagnosis, San Francisco, 2021–2025

Age at AIDS diagnosis (years)	Year of AIDS diagnosis									
	2021		2022		2023		2024		2025	
	No.	%	No.	%	No.	%	No.	%	No.	%
0 - 24	2	2.2	3	4.2	2	2.2	2	2.4	3	2.9
25 - 29	11	12.4	7	9.7	6	6.5	8	9.8	8	7.7
30 - 39	18	20.2	20	27.8	25	26.9	27	32.9	32	30.8
40 - 49	22	24.7	20	27.8	17	18.3	14	17.1	27	26.0
50 - 59	24	27.0	14	19.4	26	28.0	17	20.7	14	13.5
60+	12	13.5	8	11.1	17	18.3	14	17.1	20	19.2
Total	89	100.0	72	100.0	93	100.0	82	100.0	104	100.0

Notes:

HIV infection stage 3 (AIDS) includes new concurrent HIV-AIDS diagnoses (an AIDS diagnosis within 31 days of an HIV diagnosis), and first time AIDS diagnoses among people living with HIV who were residents of San Francisco at time of AIDS diagnosis (including persons diagnosed with HIV, non-Stage 3 and progressed to Stage 3 later).

Due to small numbers in the 0–12 and 13–17 age groups, these are not shown separately.

2025 data are incomplete due to delays in data collection, lab reporting, verification, and processing.

Preliminary HIV Surveillance Annual Report
Cases Diagnosed as of December 31, 2025 and Reported as of February 3, 2026

Table 3. Diagnoses of HIV infection by gender and year of initial HIV diagnosis, San Francisco, 2021–2025

Gender	Year of initial HIV diagnosis									
	2021		2022		2023		2024		2025	
	No.	%	No.	%	No.	%	No.	%	No.	%
Cis Men	138	77.1	142	84.0	113	80.7	111	75.0	114	82.0
Cis Women	23	12.8	14	8.3	14	10.0	27	18.2	16	11.5
Trans Women	17	9.5	12	7.1	11	7.9	9	6.1	9	6.5
Total	179	100.0	169	100.0	140	100.0	148	100.0	139	100.0

Notes:

Initial HIV diagnosis includes persons diagnosed with HIV infection regardless of disease stage. The initial year of HIV diagnosis was determined based on the earliest date of positive HIV antibody test, positive HIV antigen/antibody combination test, detectable viral load, physician-documented diagnosis in the absence of sufficient laboratory evidence, or self-report of a positive HIV test.

Data on trans men are not shown in the table but are included in the total.

2025 data are incomplete due to delays in data collection, lab reporting, verification, and processing.

Preliminary HIV Surveillance Annual Report
Cases Diagnosed as of December 31, 2025 and Reported as of February 3, 2026

Table 4. Diagnoses of HIV infection stage 3 (AIDS) by gender and year of AIDS diagnosis, San Francisco, 2021–2025

Gender	Year of AIDS diagnosis									
	2021		2022		2023		2024		2025	
	No.	%	No.	%	No.	%	No.	%	No.	%
Cis Men	69	77.5	63	87.5	80	86.0	57	69.5	92	88.5
Cis Women	11	12.4	7	9.7	9	9.7	15	18.3	6	5.8
Trans Women	8	9.0	2	2.8	4	4.3	10	12.2	6	5.8
Total	89	100.0	72	100.0	93	100.0	82	100.0	104	100.0

Notes:

HIV infection stage 3 (AIDS) includes new concurrent HIV-AIDS diagnoses (an AIDS diagnosis within 31 days of an HIV diagnosis), and first time AIDS diagnoses among people living with HIV who were residents of San Francisco at time of AIDS diagnosis (including persons diagnosed with HIV, non-Stage 3 and progressed to Stage 3 later).

Data on trans men are not shown in the table but are included in the total.

2025 data are incomplete due to delays in data collection, lab reporting, verification, and processing.

Preliminary HIV Surveillance Annual Report
Cases Diagnosed as of December 31, 2025 and Reported as of February 3, 2026

Table 5. Diagnoses of HIV infection by race/ethnicity and year of initial HIV diagnosis, San Francisco, 2021–2025

Race and ethnicity	Year of initial HIV diagnosis									
	2021		2022		2023		2024		2025	
	No.	%	No.	%	No.	%	No.	%	No.	%
White	55	30.7	44	26.0	51	36.4	39	26.4	31	22.3
Black/African American	28	15.6	24	14.2	27	19.3	41	27.7	31	22.3
Latine/x	69	38.5	78	46.2	43	30.7	47	31.8	53	38.1
Asian/Pacific Islander/Native American	24	13.4	20	11.8	19	13.6	18	12.2	19	13.7
Multi-race	3	1.7	3	1.8	0	0.0	3	2.0	3	2.2
Total	179	100.0	169	100.0	140	100.0	148	100.0	139	100.0

Notes:

Initial HIV diagnosis includes persons diagnosed with HIV infection regardless of disease stage. The initial year of HIV diagnosis was determined based on the earliest date of positive HIV antibody test, positive HIV antigen/antibody combination test, detectable viral load, physician-documented diagnosis in the absence of sufficient laboratory evidence, or self-report of a positive HIV test.

White, Black/African American, Asian/Pacific Islander, Native American, and Multiple races categories exclude Latine/x. Persons reporting Hispanic/Latino ethnicity are grouped in the Latine/x category, which refers to individuals with Latin American or Spanish ancestry, regardless of race category or identification.

Persons with unknown race/ethnicity are not shown but are included in the total.

2025 data are incomplete due to delays in data collection, lab reporting, verification, and processing.

Preliminary HIV Surveillance Annual Report
Cases Diagnosed as of December 31, 2025 and Reported as of February 3, 2026

Table 6. Diagnoses of HIV infection stage 3 (AIDS) by race/ethnicity and year of AIDS diagnosis, San Francisco, 2021–2025

Race and ethnicity	Year of AIDS diagnosis									
	2021		2022		2023		2024		2025	
	No.	%	No.	%	No.	%	No.	%	No.	%
White	29	32.6	28	38.9	34	36.6	26	31.7	34	32.7
Black/African American	15	16.9	10	13.9	14	15.1	22	26.8	19	18.3
Latinx	30	33.7	23	31.9	30	32.3	18	22.0	35	33.7
Asian/Pacific Islander/Native American	10	11.2	9	12.5	9	9.7	11	13.4	8	7.7
Multi-race	5	5.6	2	2.8	6	6.5	5	6.1	8	7.7
Total	89	100.0	72	100.0	93	100.0	82	100.0	104	100.0

Notes:

HIV infection stage 3 (AIDS) includes new concurrent HIV-AIDS diagnoses (an AIDS diagnosis within 31 days of an HIV diagnosis), and first time AIDS diagnoses among people living with HIV who were residents of San Francisco at time of AIDS diagnosis (including persons diagnosed with HIV, non-Stage 3 and progressed to Stage 3 later).

White, Black/African American, Asian/Pacific Islander, Native American, and Multiple races categories exclude Latine/x. Persons reporting Hispanic/Latino ethnicity are grouped in the Latine/x category, which refers to individuals with Latin American or Spanish ancestry, regardless of race category or identification.

Persons with unknown race/ethnicity are not shown but are included in the total.

2025 data are incomplete due to delays in data collection, lab reporting, verification, and processing.

Preliminary HIV Surveillance Annual Report
Cases Diagnosed as of December 31, 2025 and Reported as of February 3, 2026

Table 7. Diagnoses of HIV infection by transmission category and year of initial HIV diagnosis, San Francisco, 2021–2025

Transmission category	Year of initial HIV diagnosis									
	2021		2022		2023		2024		2025	
	No.	%	No.	%	No.	%	No.	%	No.	%
MSM	92	51.4	105	62.1	88	62.9	92	62.2	80	57.6
TWSM	12	6.7	12	7.1	8	5.7	7	4.7	9	6.5
PWID	18	10.1	12	7.1	9	6.4	10	6.8	11	7.9
MSM-PWID	23	12.8	17	10.1	14	10.0	9	6.1	11	7.9
TWSM-PWID	5	2.8	0	0.0	3	2.1	2	1.4	0	0.0
Heterosexual	21	11.7	12	7.1	12	8.6	24	16.2	16	11.5
Other/Unidentified	8	4.5	11	6.5	6	4.3	4	2.7	12	8.6
Total	179	100.0	169	100.0	140	100.0	148	100.0	139	100.0

Notes:

Initial HIV diagnosis includes persons diagnosed with HIV infection regardless of disease stage. The initial year of HIV diagnosis was determined based on the earliest date of positive HIV antibody test, positive HIV antigen/antibody combination test, detectable viral load, physician-documented diagnosis in the absence of sufficient laboratory evidence, or self-report of a positive HIV test.

Transmission category includes persons with more than one risk factor (other than the combinations listed in the tables) and are tabulated only in the most likely transmission category.

Heterosexuals include persons who had heterosexual contact with a person with HIV or with a person who is at risk for HIV. Heterosexual includes female presumed heterosexual.

Other/Unidentified includes risk factors not reported/identified.

2025 data are incomplete due to delays in data collection, lab reporting, verification, and processing.

Preliminary HIV Surveillance Annual Report
Cases Diagnosed as of December 31, 2025 and Reported as of February 3, 2026

Table 8. Diagnoses of HIV infection stage 3 (AIDS) by transmission category and year of AIDS diagnosis, San Francisco, 2021–2025

Transmission category	Year of AIDS diagnosis									
	2021		2022		2023		2024		2025	
	No.	%	No.	%	No.	%	No.	%	No.	%
MSM	37	41.6	38	52.8	62	66.7	40	48.8	64	61.5
TWSM	1	1.1	2	2.8	4	4.3	8	9.8	6	5.8
PWID	20	22.5	11	15.3	8	8.6	8	9.8	6	5.8
MSM-PWID	13	14.6	14	19.4	14	15.1	13	15.9	13	12.5
TWSM-PWID	6	6.7	0	0.0	0	0.0	2	2.4	0	0.0
Heterosexual	8	9.0	4	5.6	5	5.4	8	9.8	4	3.8
Other/Unidentified	4	4.5	3	4.2	0	0.0	3	3.7	11	10.6
Total	89	100.0	72	100.0	93	100.0	82	100.0	104	100.0

Notes:

HIV infection stage 3 (AIDS) includes new concurrent HIV-AIDS diagnoses (an AIDS diagnosis within 31 days of an HIV diagnosis), and first time AIDS diagnoses among people living with HIV who were residents of San Francisco at time of AIDS diagnosis (including persons diagnosed with HIV, non-Stage 3 and progressed to Stage 3 later).

Transmission category includes persons with more than one risk factor (other than the combinations listed in the tables) are tabulated only in the most likely transmission category.

Heterosexuals include persons who had heterosexual contact with a person with HIV or with a person who is at risk for HIV. Heterosexual includes female presumed heterosexual.

Other/Unidentified includes risk factor not reported/identified.

2025 data are incomplete due to delays in data collection, lab reporting, verification, and processing.

Preliminary HIV Surveillance Annual Report
Cases Diagnosed as of December 31, 2025 and Reported as of February 3, 2026

Table 9. Diagnoses of HIV infection, HIV deaths and persons living with HIV by year, San Francisco, 2002–2025

Year	Number of cases diagnosed per year	Number of deaths occurred per year	Number of persons living with HIV infection
2002	653	347	13299
2003	638	328	13609
2004	691	335	13965
2005	562	341	14186
2006	545	321	14410
2007	536	323	14623
2008	536	262	14897
2009	485	249	15133
2010	481	244	15370
2011	446	237	15579
2012	482	233	15828
2013	413	257	15984
2014	330	239	16075
2015	320	256	16139
2016	252	233	16158
2017	255	254	16159
2018	229	257	16131
2019	194	263	16062
2020	156	287	15931
2021	179	277	15833
2022	169	317	15685
2023	140	308	15517
2024	148	306	15359
2025	139	245	15253

Notes:

Mandatory reporting of HIV, non-stage 3 in California began in 2002.

2025 data are incomplete due to delays in data collection, lab reporting, verification, and processing.

Preliminary HIV Surveillance Annual Report
Cases Diagnosed as of December 31, 2025 and Reported as of February 3, 2026

Table 10. Diagnoses of HIV infection stage 3 (AIDS), AIDS deaths and persons living with AIDS by year, San Francisco, 1980–2025

Year	Number of cases diagnosed per year	Number of deaths occurred per year	Number of persons living with AIDS
1980	3	0	3
1981	26	8	21
1982	99	32	88
1983	274	111	251
1984	557	273	535
1985	859	534	860
1986	1236	807	1289
1987	1636	878	2047
1988	1762	1038	2771
1989	2159	1278	3652
1990	2043	1364	4331
1991	2283	1512	5102
1992	2325	1639	5788
1993	2058	1603	6243
1994	1774	1598	6419
1995	1543	1486	6476
1996	1055	992	6539
1997	788	424	6903
1998	680	401	7182
1999	571	352	7401
2000	551	349	7603
2001	504	324	7783
2002	478	320	7941
2003	542	292	8191
2004	476	300	8367
2005	475	307	8535
2006	450	284	8701
2007	443	269	8875
2008	434	225	9084
2009	325	207	9202
2010	301	193	9310
2011	252	190	9372
2012	243	179	9436
2013	187	190	9433
2014	140	188	9385
2015	125	203	9307
2016	97	182	9222
2017	133	202	9153
2018	116	208	9061
2019	111	192	8980
2020	91	208	8863
2021	89	203	8749
2022	72	247	8574

Preliminary HIV Surveillance Annual Report
Cases Diagnosed as of December 31, 2025 and Reported as of February 3, 2026

Table 10 cont'd. Diagnoses of HIV infection stage 3 (AIDS), AIDS deaths and persons living with AIDS by year, San Francisco, 1980–2025

Year	Number of cases diagnosed per year	Number of deaths occurred per year	Number of persons living with AIDS
2023	93	225	8442
2024	82	222	8302
2025	104	180	8226
Total	30645	22419	

Notes:

2025 data are incomplete due to delays in data collection, lab reporting, verification, and processing.

Preliminary HIV Surveillance Annual Report
Cases Diagnosed as of December 31, 2025 and Reported as of February 3, 2026

Table 11. Persons living with HIV infection by age, gender and race/ethnicity, San Francisco (as of December 31, 2025)

Current age (years)	White		Black/African American		Latine/x		Asian/Pacific Islander/Native American		Multi-race		Total		
	Cis Men	No.	%	No.	%	No.	%	No.	%	No.	%	No.	Col %
0 - 24		3	0.0	4	0.3	24	0.8	5	0.5	4	0.8	41	0.3
25 - 29		24	0.3	32	2.5	73	2.4	18	1.8	3	0.6	150	1.1
30 - 39		295	3.7	154	11.9	461	15.0	152	15.1	30	6.1	1092	7.9
40 - 49		806	10.1	167	12.9	617	20.1	234	23.2	100	20.5	1926	13.9
50 - 59		1904	23.8	277	21.4	825	26.8	311	30.9	137	28.1	3456	24.9
60+		4984	62.2	662	51.1	1077	35.0	288	28.6	214	43.9	7228	52.0
Cis Men Total		8016	100.0	1296	100.0	3077	100.0	1008	100.0	488	100.0	13893	100.0
Cis Women													
0 - 24		2	0.8	3	0.9	3	1.3	0	0.0	0	0.0	8	0.9
25 - 29		0	0.0	6	1.9	4	1.8	2	2.4	3	8.6	15	1.7
30 - 39		18	7.5	36	11.7	37	16.4	6	7.1	5	14.3	102	11.4
40 - 49		41	17.1	46	14.9	54	24.0	20	23.8	7	20.0	169	18.9
50 - 59		62	25.8	65	21.0	45	20.0	27	32.1	12	34.3	211	23.6
60+		117	48.8	153	49.5	82	36.4	29	34.5	8	22.9	390	43.6
Cis Women Total		240	100.0	309	100.0	225	100.0	84	100.0	35	100.0	895	100.0
Trans Women Total		72	100.0	129	100.0	169	100.0	55	100.0	27	100.0	452	100.0

Notes:

White, Black/African American, Asian/Pacific Islander, Native American, and Multiple races categories exclude Latine/x. Persons reporting Hispanic/Latino ethnicity are grouped in the Latine/x category, which refers to individuals with Latin American or Spanish ancestry, regardless of race category or identification.

Persons with unknown race/ethnicity are not shown but are included in the total.

Data on trans men are not shown due to the small numbers.

Due to small numbers in the 0–12 and 13–17 age groups, these are not shown separately.

2025 data are incomplete due to delays in data collection, lab reporting, verification, and processing.

Preliminary HIV Surveillance Annual Report
Cases Diagnosed as of December 31, 2025 and Reported as of February 3, 2026

Table 12. Persons living with HIV infection by transmission category, gender and race/ethnicity, San Francisco (as of December 31, 2025)

Transmission Category	White		Black/African American		Latine/x		Asian/Pacific Islander/Native American		Multi-race		Total	
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	Col %
Cis Men												
MSM	6638	82.8	838	64.7	2566	83.4	858	85.1	362	74.2	11264	81.1
PWID	138	1.7	145	11.2	61	2.0	24	2.4	14	2.9	382	2.7
MSM-PWID	1162	14.5	213	16.4	336	10.9	83	8.2	100	20.5	1895	13.6
Heterosexual	29	0.4	57	4.4	55	1.8	19	1.9	6	1.2	166	1.2
Other/Unidentified	49	0.6	43	3.3	59	1.9	24	2.4	6	1.2	186	1.3
Cis Men Total	8016	100.0	1296	100.0	3077	100.0	1008	100.0	488	100.0	13893	100.0
Cis Women												
PWID	125	52.1	126	40.8	58	25.8	12	14.3	16	45.7	337	37.7
Heterosexual	106	44.2	171	55.3	153	68.0	66	78.6	16	45.7	512	57.2
Other/Unidentified	9	3.8	12	3.9	14	6.2	6	7.1	3	8.6	46	5.1
Cis Women Total	240	100.0	309	100.0	225	100.0	84	100.0	35	100.0	895	100.0
Trans Women Total	72	100.0	129	100.0	169	100.0	55	100.0	27	100.0	452	100.0

Notes:

Transmission category includes persons with more than one risk factor (other than the combinations listed in the tables) and are tabulated only in the most likely transmission category.

Heterosexuals include persons who had heterosexual contact with a person with HIV or with a person who is at risk for HIV. Cis women heterosexual includes female presumed heterosexual.

Other/Unidentified includes risk factors not reported/identified.

Data on trans men are not shown due to the small numbers.

White, Black/African American, Asian/Pacific Islander, Native American, and Multiple races categories exclude Latine/x. Persons reporting Hispanic/Latino ethnicity are grouped in the Latine/x category, which refers to individuals with Latin American or Spanish ancestry, regardless of race category or identification.

Persons with unknown race/ethnicity are not shown but are included in the total.

2025 data are incomplete due to delays in data collection, lab reporting, verification, and processing.